What’s your role in Business Strategies? Are you struggling to stay ahead in the competition? How do you adhere to the gap between strategic intelligence and decision making?
Aimed to position you and your company ahead of the competition,MarketsandMarkets Competitive and Market Intelligence Summit will establish business intelligence that pertains to the best business strategies identifying the right fuel to shoot your strategic decision making. Discover advances in Market Intelligence/Competitive Intelligence/Business Intelligence tools & techniques from world's leading strategists across various industries along with use case implications, best outcome envisions and proactive strategy development.
In a constantly evolving innovative time, companies continue to wrestle for deriving more value from their “business and corporate strategies”. The significance of a business strategy relies on it being a viable way to build up business desires, creating a competitive advantage and additionally increment shareholder value to something beyond the aggregate of its physical resources. MarketsandMarkets Chief Strategy Officer Forum invites leading strategy executives from Fortune 2000 companies who are making the future.
Drug product development for highly potent APIs (HPAPIs) can be challenging. Complications with the interface between operations in drug substance and drug product handling can result in increased program complexity and cost. The growth in this market is driven by factors such as increasing demand for oncology drugs, growing demand for antibody-drug conjugates, increasing focus of leading pharmaceutical companies on HPAPIs, advancements in HPAPI manufacturing technologies, and growing focus on precision medicine. This year’s conference will focus on case studies related to development, rapid scaling, validation and commercial production of HPAPI drug substance, as well as integrated containment requirements for particle engineering and drug product.
Artificial Intelligence (AI) is changing the ecosystem in the automotive industry along with other applications in everyday life in 21st Century. The battleground to win the customers is one of driving force for automotive manufacturers and OEMs to adopt the new technology and lead the marketplace. After the success of inaugural congress held in Silicon Valley in May 2018, this year, we are aiming to provide a platform to experts from automotive industry, academia, and government institutions discussing the innovations, challenges, and future aspects of innovative technologies in automotive.
Biomarker is constantly evolving as the latent for the development of innovative drugs and diagnostic assays for early detection of disease. The major developments are witnessed in immune therapies where breakthroughs will be appearing soon.
The 4th Annual Biomarker and Companion Diagnostics Conference scheduled to be held on 7th-8th February 2019 in San Diego, CA would address the gaps between early stage biomarker development and the commercialization stage of biomarkers. Regarding commercialization of biomarkers, leading industry and academic experts would share their case studies focusing on advancements in the companion diagnostics area. The keynote presentations would also help the attendees understand the issues related to clinical translation of biomarkers.
The next big question in cancer immunotherapy is what’s next in immuneoncology?
Overcoming resistance to various combinatorial approaches, selecting the patients and developing translational hypothesis besides designing optimal preclinical models for immunological agents, different strategies to regulate the microbiome are some of the major challenges faced by cancer research experts in the US.
Following the success of our UK Edition, MarketsandMarkets is proud to announce the Next Gen Immuno-Oncology Congress-US Edition to be held on 21st and 22nd June 2018 in Philadelphia, USA. The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to address the latest updates in development of CAR-T cell therapy, neoantigen-based and microbiomederived immunotherapy and new paradigms in immune checkpoint inhibitors